Denmark
SOLID Therapeutics, an early-stage oncology company with a focus on treating solid tumors, emerges as a promising player in the biotechnology arena. Spun out from the CBMR at the University of Copenhagen, this innovative startup is harnessing cutting-edge therapeutics with a dual mode of action. The approach targets both cancer and immune cells, presenting unique advantages in the complex oncology landscape.
Founded in 2022 and headquartered in Denmark, SOLID Therapeutics intersects the biotechnology and health care industries with potential to significantly impact both sectors. The company recently secured a Convertible Note investment on 05 September 2023 from BioInnovation Institute, marking a pivotal step in their growth trajectory.
For venture capitalists and investors, SOLID Therapeutics’ innovative approach and strong ties with leading research institutions position it as an early-stage opportunity with substantial promise in transforming cancer treatment paradigms.
